Screener
Veracyte VCYT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Deferred tax liabilities | 636 | 646 |
| Acquisition-related contingent consideration, net of current portion | 257 | 257 |
| Operating lease liabilities, net of current portion | 34,986 | 35,603 |
| Total liabilities | 91,994 | 96,443 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 80 | 79 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's total liabilities?
- Veracyte (VCYT) reported total liabilities of $91.99M in Q1 2026.
- How has Veracyte's total liabilities changed year-over-year?
- Veracyte's total liabilities decreased by 23.6% year-over-year, from $120.48M to $91.99M.
- What is the long-term trend for Veracyte's total liabilities?
- Over 5 years (2020 to 2025), Veracyte's total liabilities has grown at a 21.8% compound annual growth rate (CAGR), from $35.93M to $96.44M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Veracyte's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude